Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

2002 ◽  
Vol 51 (10) ◽  
pp. 539-546 ◽  
Author(s):  
Brigitte Dréno ◽  
Jean-Michel Nguyen ◽  
Amir Khammari ◽  
Marie Pandolfino ◽  
Marie Tessier ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Melanoma Tumor ◽  
Stage Iii Melanoma ◽  
Infiltrating Lymphocytes

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

2007 ◽  
Vol 56 (11) ◽  
pp. 1853-1860 ◽  
Author(s):  
Amir Khammari ◽  
Jean-Michel Nguyen ◽  
Marie Christine Pandolfino ◽  
Gaëlle Quereux ◽  
Anabelle Brocard ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Melanoma Tumor ◽  
Long Term Follow Up ◽  
Stage Iii Melanoma ◽  
Infiltrating Lymphocytes

scholarly journals Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

The Lancet ◽  
2008 ◽  
Vol 372 (9633) ◽  
pp. 117-126 ◽  
Author(s):  
Alexander MM Eggermont ◽  
Stefan Suciu ◽  
Mario Santinami ◽  
Alessandro Testori ◽  
Wim HJ Kruit ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Phase Iii ◽  
Stage Iii ◽  
Phase Iii Trial ◽  
Pegylated Interferon Alfa ◽  
Stage Iii Melanoma ◽  
Resected Stage

Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 9577-9577
Author(s):  
Michael B. Atkins ◽  
Cristina Julian ◽  
Matthew H. Secrest ◽  
Janet Lee ◽  
Ana Maria Abajo Guijarro ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Checkpoint Inhibitors ◽  
The United States ◽  
Distant Recurrence ◽  
Advanced Melanoma ◽  
Stage Iii ◽  
Braf Mutations ◽  
Stage Iii Melanoma ◽  
Resected Stage ◽  
Braf Mutant

9577 Background: The management of patients with resected stage III melanoma has changed in recent years, and real-world data on recurrence patterns and adjuvant therapy responses are scarce. This study assessed adjuvant treatment patterns and outcomes in patients with advanced melanoma by BRAF status and relapse location. Methods: Patients diagnosed with stage III advanced melanoma between January 2011 and February 2020 in the nationwide Flatiron Health electronic health record–derived deidentified database were included if they were ≥18 years, received approved first-line (1L) adjuvant therapy after January 2018 with checkpoint inhibitors (CPIs; eg, nivolumab, pembrolizumab) or targeted therapies (TTs; eg, dabrafenib/trametinib), had 6 months’ follow-up and had ≥1 visit after starting adjuvant therapy (Cohort 1). Patients from Cohort 1 were included in Cohort 2 if they had a recurrence following initiation of adjuvant therapy, and those from Cohort 2 were included in Cohort 3 if they had a distant recurrence and available documented BRAF status at any time. Time to next systemic treatment (TTNT), overall survival (OS) and relapse free survival (RFS) were estimated using Kaplan-Meier (KM) methods from adjuvant therapy start (Cohort 1), first recurrence date (Cohort 2) or first distant recurrence date (Cohort 3). Results: Cohort 1 included 447 patients receiving 1L adjuvant therapy; Cohort 2 included patients after first distant (n = 47) or local (n = 35) relapse; Cohort 3 included distant-recurrent patients with tumors that were BRAF wild type (WT) (n = 22) or BRAF mutant (n = 23). The majority of patients were aged < 65 years. Across cohorts, relative use of TTs vs CPIs was similar: Cohort 1 (4.5% vs 96%), Cohort 2 (2.4% vs 98%) and Cohort 3 (2.2% vs 98%). Nivolumab was the most frequent treatment used across cohorts (84%-88%). In Cohort 1, 1- and 2-year KM probabilities for OS, RFS and TTNT were 93.5%/83.8%, 83.2%/70.6% and 84.0%/62.4%, respectively. In Cohort 2, for patients with local recurrence, 6- and 12-month OS probabilities were 93.4% and 78.8%, respectively, which were substantially higher than those for patients with distant recurrence (64.5% and 46.9%). In Cohort 3, for patients with documented BRAF mutations, 6- and 12-month OS rates from disease recurrence were 79.1% and 49.4%, respectively, which were greater than for those with BRAF-WT tumors (54.1% and 46.3%). Conclusions: Early RFS and OS outcomes for patients with surgically resected Stage III melanoma appear comparable to those reported in randomized clinical studies. The majority of patients with advanced melanoma, including patients who experienced recurrence, initiated treatment with CPIs. OS rates were numerically greater for Cohort 3 patients with BRAF-mutant tumors. Outcomes for patients with distant recurrence after adjuvant therapy remain unfavorable and represent a continued unmet medical need.

scholarly journals Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)

PLoS ONE ◽  
2010 ◽  
Vol 5 (11) ◽  
pp. e13940 ◽  
Author(s):  
Linh T. Nguyen ◽  
Pei Hua Yen ◽  
Jessica Nie ◽  
Nicole Liadis ◽  
Danny Ghazarian ◽  
...  
Keyword(s):  
Tumor Infiltrating Lymphocytes ◽  
Human Melanoma ◽  
Melanoma Tumor ◽  
Infiltrating Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document